The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burshtyn, D. N.
Right arrow Articles by Long, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burshtyn, D. N.
Right arrow Articles by Long, E. O.
The Journal of Immunology, 1999, 162: 897-902.
Copyright © 1999 by The American Association of Immunologists

Conserved Residues Amino-Terminal of Cytoplasmic Tyrosines Contribute to the SHP-1-Mediated Inhibitory Function of Killer Cell Ig-Like Receptors

Deborah N. Burshtyn, Alan S. Lam, Margaret Weston, Neetu Gupta, Petra A. M. Warmerdam1 and Eric O. Long2

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The sequence I/VxYxxL, often referred to as an immunoreceptor tyrosine-based inhibition motif (ITIM), binds to the C-terminal Src homology 2 domain of the tyrosine phosphatase SHP-1. Conserved residues N-terminal of the tyrosine are not ordinarily found in other Src homology 2 domain binding motifs. The inhibitory forms of killer cell Ig-like receptors (KIR) contain two ITIMs. The role of each ITIM, and of the conserved residues upstream of the tyrosine, in the inhibition of NK cells was tested by vaccinia virus-mediated expression of mutant KIRs. Substitution of the tyrosine in the membrane-proximal ITIM abrogated the ability of KIR to block Ab-dependent cellular cytotoxicity, whereas mutation of the membrane-distal ITIM tyrosine had little effect. Substitution of the conserved hydrophobic amino acid that was located two residues N-terminal to the tyrosine weakened, but did not eliminate, the function of the receptor. In contrast, these substitutions drastically reduced the amount of SHP-1 immunoprecipitated with KIR, suggesting that weak interactions with SHP-1 may be sufficient for inhibition.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Killer cell Ig-like receptors (KIRs)3 are a family of HLA class I-specific receptors that can inhibit or activate NK cells and a subset of T lymphocytes. Inhibitory KIRs prevent activation of NK cells upon binding to HLA class I molecules expressed on the target cells. The mechanism of KIR-mediated inhibition involves recruitment of the tyrosine phosphatase SHP-1 (1, 2, 3). SHP-1 is expressed primarily in hematopoietic cells and plays an important role in regulation of the immune system. Motheaten mice have a natural defect in SHP-1 expression and display severe disregulation of several hematopoietic cell types (4). SHP-1 has been implicated in the down-regulation of several signaling cascades such as those induced by erythropoietin, IL-3, and steel factor (4). The relevant target molecule of SHP-1 activity during KIR-mediated inhibition of NK cells is not yet known and may vary depending on the particular pathway of activation. SHP-1 has relatively broad catalytic specificity in vitro. In vivo, SHP-1 has been proposed to dephosphorylate Jak2 (5), ZAP70 (6), syk, the {gamma}-chain of the CD16 complex (3), and the pp36 molecule (7) that may be the recently cloned LAT (8). The activity of the catalytic domain of SHP-1 is regulated by its tandem Src homology 2 (SH2) domains (9, 10). Phosphopeptides that bind to the N-terminal SH2 domain induce the phosphatase activity, suggesting that recruitment of SHP-1 through its SH2 domains would lead to localized activation of SHP-1. Therefore, the specificity of the SH2 domains is a critical determinant of where and when SHP-1 is active.

The consensus motif I/VxYxxL/V was deduced from the sequences of several receptors known to bind to the C-terminal SH2 domain of SHP-1 (1, 11). This ITIM occurs in NK receptors such as KIR, Ly49, NKG2A, and gp49B; in B cell receptors such as CD22, Fc{gamma}RIIb, and PIR; and in receptors expressed in monocytes and dendritic cells such as ILT/MIR/LIR (reviewed in Refs. 12 and 13). The tyrosines in the cytoplasmic tail of KIR, PIR, and Ly49A are required for inhibition (14, 15, 16, 17). The involvement of upstream residues in a binding motif for an SH2 domain was unprecedented. In vitro analysis with phosphopeptides has established that the conserved residues both upstream and downstream of the motif are important for binding to the C-terminal SH2 domain of SHP-1 (1, 18). Furthermore, a longer peptide with two phosphorylated ITIMs produced greater activation of SHP-1 than the combination of two shorter peptides, each carrying a separate ITIM (10). We have performed mutagenesis of the ITIMs in KIR to assess the relative importance of each ITIM and of the conserved I/V amino acid N-terminal of the tyrosine in the functional context of MHC class I-mediated inhibition of NK cells.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cells, Abs, and reagents

The cell line 721.221 (19) was provided by R. DeMars, and the transfected 721.221 cell line .221-Cw3 (20) was provided by J. Gumperz and P. Parham. HEK 293T/17 cells were obtained from American Type Culture Collection (Manassas, VA) (21). Mouse NK cells were isolated from 4–6-month-old C57BL/6 mice as described (22). Briefly, nylon wool nonadherent cells were stimulated with 800 U/ml human rIL-2. On day 3 the plastic adherent cells were retained and restimulated with rIL-2. Purity was assessed by flow cytometry on day 6 with anti-NK1.1 and phycoerythrin-coupled anti-mouse CD3 (PharMingen, San Diego, CA). Cells were >99% NK1.1+ and ranged from 10 to 33% CD3+. Cytotoxicity assays were performed on day 7 or 8. Biochemical analysis of receptors was done on day 11. The mAb GL183 (Immunotech, Westbrook, ME) is an IgG1 reactive with the ectodomain of KIR-2DL3, and CH-L (23) is an IgG2b with similar specificity (a kind gift of S. Ferrini). MOPC21 is an IgG1 used as a control for immunoprecipitation and flow cytometric analysis (Sigma, St. Louis, MO). Western blotting was performed with polyclonal anti-SH-PTP1 reactive with human and mouse SHP-1- and biotin-conjugated 4G10 specific for phosphotyrosine (Upstate Biotechnology, Lake Placid, NY). Western blots were developed with horseradish peroxidase-goat anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA) or horseradish peroxidase-streptavidin and the enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL).

Mutagenesis of KIR2DL3

The double-tyrosine mutant Y2F of KIR2DL3 (formerly known as KIR-6) has been described (15). Mutagenesis was performed using the Transformer Mutagenesis Kit (Clontech, Palo Alto, CA) in the plasmid RSV.5 (24). The fragment was subcloned into the vector pSC65 modified to include SalI–NotI cloning sites and used for recombination with vaccinia strain WR (25). The single tyrosine-to-phenylalanine mutant Y312F was generated as the first step for making Y2F, and the SalI–StuI fragment was subcloned into the modified pSC65. All other mutagenesis was done with the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) following the manufacturer’s guidelines. All mutagenic primers contained 10–15 flanking residues. The remainder of the mutagenesis was performed on the KIR2DL3 cDNA sequence in the vector pSPORT (26). Y282F was generated with the same forward mutagenic primer as described for Y2F (15) and the complementary reverse primer. The mutants 280A (Val280 to Ala) and 310A (Ile310 to Ala) were generated by the codon substitutions of GTG to GCG and ATC to GCC, respectively. To create the mutant -2A2, the 310A mutation was introduced into the 280A mutant. 310A/282F was created by introducing the 282F mutation onto the 310A in pSPORT. The SalI–NotI fragment of all mutants generated in pSPORT was subcloned into the modified pSC65. Introducing the 280A mutation into the 312F mutant in pSC65 created 280A/312F. The mutations were confirmed by sequence analysis. A silent mutation arose in the 282F in the region of the mutagenic primer. The entire coding sequence of each final product was verified to ensure that no other mutation was introduced into the receptors.

Infection with recombinant vaccinia viruses

Generation of recombinant vaccinia virus was as described (25). All vaccinia viruses were purified, and the titer in plaque-forming units (pfu) was determined in TK- cells. Mouse NK cells were used between days 7 and 9 of culture for cytotoxicity assays. For each condition, 750,000 cells were infected in 0.5 ml of Iscove’s medium supplemented with 0.1% BSA, nonessential amino acids, 2 mM glutamine, and 100 U/ml recombinant IL-2. The duration of the infection was 1.5–2 h at 37°C with 5% C02. The cells were washed once in 10 ml of warm assay medium (Iscove’s medium with 5% FBS, glutamine, and gentamicin). The cells were counted and diluted into assay medium with 100 U/ml rIL-2 at the appropriate concentration for E:T ratios of 9 and 3. NIH-3T3 cells were infected with crude preparations of recombinant vaccinia as described (1).

Immunoprecipitation

Infected cells were washed once with Dulbecco’s PBS and resuspended in Dulbecco’s PBS with 0.03% H2O2 and 0.2 µM NaV03 and incubated at 37°C for 10 min. The cells were pelleted and lysed in 0.5 ml of 0.5% Triton X-100, 150 mM NaCl, 1 mM EDTA, 10 µg/ml aprotinin, 1 mM pepstatin A, 1 mM NaVO3, 1 mM NaF, 5 mM iodoacetamide, 1 mM PMSF, and 20 mM Tris-HCl, pH 8. Debris was removed from the lysates by a 20-min centrifugation at 4°C. Receptors were immunoprecipitated by a 30-min incubation with 5 µg of GL183 and collected for 20 min with protein G bound to agarose beads (Life Technologies, Grand Island, NY). The pellets were washed three times with 1 ml of lysis buffer and analyzed by 10.5% SDS-PAGE under nonreducing conditions and immunoblotting.

Transient transfection

lck505F in the vector pSXSR{alpha} (27) was a gift from L. Samelson. Wild-type and mutant KIR2DL3 were expressed from the plasmid RSV.5 (24). One day before transfection, HEK 293T/17 cells were plated at 5 x 105 cells per well in six-well plates in DMEM supplemented with 10% FBS and 2 mM L-glutamine. Cells were transfected with 2 µg of each plasmid using the CellPhect transfection kit calcium phosphate reagents prepared essentially according to the manufacturer’s instructions (Pharmacia Biotech, Piscataway, NJ). The DNA mixture was added to the wells in 1 ml of culture medium with 40 µM of chloroquine and incubated for 5 h. The monolayer was washed twice with medium and cultured for 48 h before analysis. Cells were removed from the plastic with PBS containing 1 mM EDTA, and 5% of the recovered cells were used for flow cytometric analysis. The remaining cells were lysed and immunoprecipitated with GL813 as described, except that the samples were precleared overnight in the presence of 5 µg of MOPC21 and protein G-agarose beads.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Tyrosine mutations

KIR2DL3, a member of the KIR family, is specific for HLA-Cw3. The two tyrosine residues in the cytoplasmic tail of KIR2DL3 were mutated to phenylalanine independently and in combination (Fig. 1Go). Receptor function was evaluated in mouse NK cells that were mixed with human target cells coated with Abs to induce Ab-dependent cellular cytotoxicity (ADCC) through the Fc{gamma}RIII receptor. Mutated receptors expressed by recombinant vaccinia viruses were compared at a multiplicity of infection of 20 pfu/NK cell, which produced comparable levels of surface expression for all of the receptors. Mutation of the membrane-distal tyrosine (312F) had little to no effect on the ability of the receptor to inhibit an activation signal delivered by the Fc receptor (Fig. 2Go). The data in Fig. 2Go represent activation with the highest dose of Ab and suggest that 312F is still able to deliver an inhibitory signal under strong NK activation conditions. In contrast, the receptor in which the membrane-proximal tyrosine was mutated (282F) was unable to provide inhibition under the same conditions. The inhibitory activity of mutant 282F was similar to that of KIR2DL3 without a cytoplasmic tyrosine (Y2F). Similar results were obtained at a 10-fold lower dose of Ab (data not shown).



View larger version (11K):
[in this window]
[in a new window]
 
FIGURE 1. Mutants of KIR2DL3. The sequence represents the entire cytoplasmic tail of KIR2DL3 (residues 245–320). ITIM consensus sequences are indicated at the top.

 


View larger version (13K):
[in this window]
[in a new window]
 
FIGURE 2. The membrane-proximal tyrosine of KIR2DL3 is necessary for inhibition of ADCC in NK cells. Mouse NK cells were either uninfected ({blacksquare}) or infected at 20 pfu per cell with vaccinia virus expressing wild type ({square}), Y282F ({blacktriangleup}), Y312F ({triangleup}), or Y2F (•). Cells were infected for 1.5 h and assayed for the ability to lyse .221 and .221-Cw3 cells coated with L243 mAb at 0.1 µg/ml in a 4-h assay of 51Cr release. The level of receptor expressed at the cell surface at the beginning of the lysis assay was assessed with the mAb GL183. The mean fluorescence intensity in this experiment was 9 for uninfected cells; 240 for cells infected with wild type; and 257 for Y282F, 263 for Y312F, and 258 for Y2F cells. Each condition was tested in triplicate, and the experiment presented is representative of three independent experiments.

 
Mutation of the I/V residues N-terminal of the ITIM tyrosine

A mutant of KIR2DL3 was constructed with Ala residues substituted for the Val280 and Ile310 upstream of the tyrosines and named -2A2 (Fig. 1Go). The role of position -2 was also tested in the context of the first Tyr alone by substituting Ala for Val280 in conjunction with the mutation of Tyr312 to Phe (280A/312F) (Fig. 1Go). Recombinant vaccinia viruses were employed to obtain expression of these mutant receptors in mouse NK cells, and the strength of the inhibitory signal was tested in a cytotoxicity assay (Fig. 3Go). A similar level of surface expression for 280A/312F and -2A2 required ~10-fold higher doses of virus than for the wild-type or the Tyr-to-Phe mutants of KIR2DL3 (Fig. 3GoA and Table IGo). Flow cytometry was used to determine the dose necessary to obtain matched levels of receptor. Two doses of 280A/312F are included in Fig. 3Go for comparison. The mouse cells displayed a low level of natural cytotoxicity toward .221 and .221-Cw3 cells in the absence of Abs. This low killing activity was inhibited by all mutant receptors except Y2F. However, the ability of the mutant receptors to prevent killing of .221-Cw3 cells decreased as activation through ADCC was increased by addition of Ab specific for target cells. The strength of inhibition by 280A/312F and -2A2 correlates with the relative affinities for binding to SHP-1 of phosphopeptides corresponding to the various mutant receptors (10).



View larger version (17K):
[in this window]
[in a new window]
 
FIGURE 3. The conserved I/V at position -2 contributes to the strength of the inhibitory signal. A, Flow cytometric analysis of relative receptor expression at the cell surface of vaccinia virus-infected mouse NK cells after 2 h of infection assessed by staining with GL183. The dose of vaccinia and the mean fluorescence intensity are listed in Table IGo. B, Lysis of .221 and .221-Cw3 cells in the absence of Ab (top), with 0.1 (middle), or with 1.0 µg/ml L243 (bottom). The effector cells expressing wild type ({square}), Y312F ({triangleup}), 280A/312F at 32 pfu/cell ({blacklozenge}), 280A/312F at 48 pfu/cell ({lozenge}), -2A2 ({circ}), and Y2F (•), as well as the uninfected cells ({blacksquare}), correspond to those depicted in A. The 51Cr release was measured after 3 h; all points were assayed in duplicate. The data are representative of five experiments.

 

View this table:
[in this window]
[in a new window]
 
Table I. Cell surface expression of receptors

 
Association of SHP-1 with mutant ITIMs

To test the ability of the various receptors to coprecipitate SHP-1, mouse NK cells were infected with vaccinia viruses encoding the receptors and treated with pervanadate to induce tyrosine phosphorylation (28). Mutation of either tyrosine alone decreased the amount of tyrosine phosphorylation detectable by Western blotting to less than half (Fig. 4Go, middle). This low level of phosphorylation may be due to a different efficiency of phosphorylation by the relevant kinases or to a diminished ability of the Ab 4G10 to bind to a monophosphorylated protein. In addition, despite treatment of the cells with pervanadate, protection from phosphatases by stronger binding of SH2 domains to a biphosphorylated tail than to a monophosphorylated one cannot be ruled out. Similar results were observed in mouse 3T3 cells that lack SHP-1 (data not shown). However, phosphorylation of -2A2 was very similar to that of the wild-type receptor, indicating that mutation of residues at position -2 did not affect overall phosphorylation or dephosphorylation. On the other hand, mutation of these residues reduced the amount of SHP-1 immunoprecipitated, with the receptor below the limit of detection. Even long exposures did not reveal SHP-1 associated with -2A2, 282F, or 312F. A similar amount of receptor in each sample was detected with the mAb CH-L (Fig. 4Go), which binds to the extracellular domain of KIR2DL3.



View larger version (56K):
[in this window]
[in a new window]
 
FIGURE 4. Mutations at position -2 affect SHP-1 coprecipitation but not tyrosine phosphorylation. Mouse NK cells (4.5 x 106 cells per lane) were infected with recombinant vaccinia viruses at the following doses in pfu/cell: wild type, 5; Y2F, 4.5; -2A2, 24; 312F, 4; 280A/213F, 24; 282F, 5; and 310A/282F, 24. After 4.5 h, an aliquot was removed to determine surface expression. The mean fluorescence intensities were 7 for uninfected cells, 391 for wild type, 554 for Y2F, 638 for -2A2, 498 for 312F, 355 for 280A/213F, 517 for 282F, and 355 for 310A/282F. All samples were treated with pervanadate for 10 min at 37°C and lysed, and the receptor was immunoprecipitated with mAb GL813. Samples were divided into two lanes, resolved by 10% SDS-PAGE without reduction, and transferred to polyvinylidene difluoride membrane for Western blotting analysis for SHP-1 or phosphotyrosine. Each membrane was reprobed with CH-L (the membrane used first for SHP-1 is shown at bottom).

 
Treatment with pervanadate may not always produce the same tyrosine phosphorylation pattern as receptor activation. Therefore, it was important to establish how a physiologically relevant kinase phosphorylates the mutated KIR. Phosphorylation of KIR in NK cells is thought to be mediated by lck (3). As the amount of phosphorylation produced during Ab-mediated cross-linking of KIR2DL3 is very low in NK cells (Ref. 1 and D.N.B., unpublished observations), we tested the ability of active lck to phosphorylate the 312F mutant in transfected cells. KIR2DL3 and the mutant receptors were cotransfected with a constitutively active form of lck (lck505F) into 293T/17 cells (Fig. 5Go). lck505 produced much higher phosphorylation of the wild-type receptor compared with the 312F mutant, in agreement with the data obtained in pervanadate-treated cells.



View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 5. Phosphorylation of KIR2DL3 tyrosine mutants by lck505F. A, Flow cytometric analysis of surface expression of KIR2DL3 and the mutated receptors transfected into HEK 293T/17 cells in the absence (none) or the presence (lck505F) of constitutively active lck. B, Samples corresponding to those in A were lysed and immunoprecipitated with mAb GL183. The samples were reduced and analyzed by Western blotting with anti-phosphotyrosine. The arrow indicates the position of KIR2DL3. The relative phosphorylation was similar in four independent experiments.

 
The lack of detectable SHP-1 in KIR immunoprecipitations from NK cells seems inconsistent with the inhibition observed by mutants 312F and -2A2. However, vaccinia virus-infected NIH-3T3 cells, in which both the receptors and SHP-1 can be expressed at high levels, revealed a weak association (Fig. 6Go). The amount of SHP-1 associated with -2A2 was much smaller than that associated with the wild-type receptor (Fig. 6Go).



View larger version (37K):
[in this window]
[in a new window]
 
FIGURE 6. SHP-1 association with KIR2DL3 by reconstitution in fibroblasts. NIH-3T3 cells were infected for 5 h using 5 pfu/cell of vaccinia virus encoding SHP-1 and wild-type KIR2DL3 (WT) or the mutants Y2F and -2A2. The samples were treated with pervanadate and lysed, and the receptor complexes were immunoprecipitated and analyzed by Western blot as described in Materials and Methods. The Ab used in each Western blot is indicated to the left of each panel, and the position of the molecular mass markers (kDa) is indicated on the right.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The motif I/VxYxxL has been used to predict SHP-1 binding and an inhibitory role for a growing number of receptors, many of which are without known ligands or function (13). We have previously determined the importance of the conserved residues in this ITIM in terms of binding to and activation of SHP-1 in vitro (10). We have now addressed their contribution to the function of KIR in NK cells.

Our results indicate that inhibition of ADCC requires the membrane-proximal tyrosine but not the membrane-distal tyrosine. A similar analysis of a chimeric molecule consisting of the extracellular domain of CD8 and a KIR cytoplasmic tail concluded that the membrane-proximal tyrosine was sufficient for inhibition of TCR activation of NFAT in Jurkat T cells (14). However, the CD8 chimeric receptor lacking the membrane-proximal tyrosine (corresponding to our 282F receptor) retained partial inhibitory activity in Jurkat cells (14). The difference with our results may relate to the nature or the efficiency of the inhibitory signal required to block cytotoxicity by NK cells as compared with transcriptional activation in T cells. An alternative explanation is that the single membrane-distal tyrosine is sufficient to provide an inhibitory signal when included in a receptor expressed as a homodimer, such as CD8, but not when present in the tail of a monomeric receptor such as KIR. Despite this difference, both studies show that the membrane-proximal ITIM is more potent than the membrane-distal ITIM. This conclusion is supported by the observation that a synthetic phosphopeptide corresponding to the membrane-proximal tyrosine binds SHP-1 with greater affinity than a peptide corresponding to the membrane-distal tyrosine (10, 18). It is noteworthy that the membrane-proximal tyrosine is in the context of the sequence QE(I/V)TYAQL that is conserved in a subset of the receptor families that bind SHP-1 such as PIR, ILT/MIR/LIR, Ly-49, and NKG2 (reviewed in 13 .

The mutant receptors carrying a single tyrosine were weakly phosphorylated in pervanadate-treated NK cells, as compared with the wild-type receptor, and did not coimmunoprecipitate SHP-1. Phosphorylation of receptors with a single tyrosine was also weak in cotransfection experiments with an active form of lck, the kinase believed to be responsible for phosphorylation of KIR (3). Despite weak tyrosine phosphorylation, the 312F mutant receptor was fully inhibitory when expressed in NK cells. These results reveal limitations in extrapolation of function from detection of protein-protein complexes by coimmunoprecipitation and emphasize the necessity to test mutant receptors in functional assays. A similar requirement for two tyrosines in the biliary glycoprotein (CD66a) for interaction with SHP-1 has been reported (29).

The residues at position -2 from the tyrosine contribute to the strength of the signal delivered by KIR but are not an absolute requirement for inhibition. The degree of inhibition delivered by mutants -2A2 and 280A/312F parallel the ability of phosphopeptides corresponding to these sequences to bind and activate SHP-1 in vitro (10). The I/V at position -2 is important for maintaining the association of KIR and SHP-1 in detergent lysates. The -2A2 mutant receptor was phosphorylated as well as the wild-type receptor, yet we failed to detect SHP-1 in association with -2A2 in NK cells. However, an association of SHP-1 with -2A2 was observed after overexpression of the molecules in heterologous cells. These results suggest that SHP-1 mediates the inhibition by -2A2 but do not rule out the possibility that another molecule binding to the mutants can substitute for SHP-1. However, we have not observed association of the mutants with likely candidates such as SHP-2 or SHIP (18, 30) (data not shown). The importance of position -2 for SHP-1 association may depend on the particular ITIM and may be compensated by the presence of more than one SHP-1 binding motif in the receptor. The overall avidity of SHP-1 for a peptide carrying two phosphorylated ITIMs is greater than the sum of the affinities for each individual phosphorylated ITIM (10). Consistent with this in vitro finding, the mutant -2A2 with tyrosines was a stronger inhibitor than either mutant 282F or mutant 280A/312F that have a single tyrosine.

An unexpected observation was that mutation of the I/V at position -2 affects the surface expression of KIR. The reduced surface expression occurred when either Val280 or Ile310 was mutated to Ala, suggesting that these mutations exposed a cryptic determinant in the sequence that perturbs surface expression levels. Matched surface expression levels required higher doses of recombinant vaccinia virus for the receptors mutated at position -2. Despite greater doses of recombinant vaccinia virus, the total cellular pool of KIR detected by immunoprecipitation and Western blotting was not greater. This observation would be consistent with a faster turnover of the mutated KIR. Further analysis is required to determine the underlying mechanism and the implications for receptors with similar sequences.


    Acknowledgments
 
We thank B. Moss, S. Ferrini, R. DeMars, J. Gumperz, and P. Parham for kind gifts of reagents; W. Clark and M. Sandusky for assistance with the sequence analysis; A. Scharenberg and N. Wagtmann for assistance in generating recombinant vaccinia viruses; and D. McVicar and members of L. Samelson’s laboratory for helpful discussions. Human rIL-2 was a gift from Hoffmann-La Roche (Nutley, NJ).


    Footnotes
 
1 Present address: Department of Molecular and Vascular Biology, Campus Gasthuisberg, O&N, Leuven, Belgium. Back

2 Address correspondence and reprint requests to Dr. Eric Long, LIG-NIAID-NIH Twinbrook II, 12441 Parklawn Drive, Rockville, MD 20852-1727. E-mail address: Back

3 Abbreviations used in this paper: KIR, killer cell Ig-like receptor; ITIM, immunoreceptor tyrosine-based inhibitory motif; SH2, Src homology 2; pfu, plaque-forming unit; ADCC, antibody-dependent cellular cytotoxicity. Back

Received for publication May 26, 1998. Accepted for publication October 2, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Burshtyn, D. N., A. M. Scharenberg, N. Wagtmann, S. Rajagopalan, K. Berrada, T. Yi, J. P. Kinet, E. O. Long. 1996. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4:77.[Medline]
  2. Campbell, K. S., M. Dessing, M. Lopez-Botet, M. Cella, M. Colonna. 1996. Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. J. Exp. Med. 184:93.[Abstract/Free Full Text]
  3. Binstadt, B. A., K. M. Brumbaugh, C. J. Dick, A. M. Scharenberg, B. L. Williams, M. Colonna, L. L. Lanier, J. P. Kinet, R. T. Abraham, P. J. Leibson. 1996. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 5:629.[Medline]
  4. Neel, B. G.. 1997. Role of phosphatases in lymphocyte activation. Curr. Opin. Immunol. 9:405.[Medline]
  5. Klingmüller, U., U. Lorenz, L. C. Cantley, B. G. Neel, H. F. Lodish. 1995. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729.[Medline]
  6. Plas, D. R., R. Johnson, J. T. Pingel, R. J. Matthews, M. Dalton, G. Roy, A. C. Chan, M. L. Thomas. 1996. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272:1173.[Abstract]
  7. Valiante, N. M., J. H. Phillips, L. L. Lanier, P. Parham. 1996. Killer cell inhibitory receptor recognition of human leukocyte antigen (HLA) class I blocks formation of a pp36/PLC-{gamma} signaling complex in human natural killer (NK) cells. J. Exp. Med. 184:2243.[Abstract/Free Full Text]
  8. Zhang, W., J. Sloan-Lancaster, J. Kitchen, R. P. Trible, L. E. Samelson. 1998. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92:83.[Medline]
  9. Pei, D. H., J. Wang, C. T. Walsh. 1996. Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1. Proc. Natl. Acad. Sci. USA 93:1141.[Abstract/Free Full Text]
  10. Burshtyn, D. N., W. T. Yang, T. L. Yi, E. O. Long. 1997. A novel phosphotyrosine motif with a critical amino acid at position -2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1. J. Biol. Chem. 272:13066.[Abstract/Free Full Text]
  11. Olcese, L., P. Lang, F. Vély, A. Cambiaggi, D. Marguet, M. Bléry, K. L. Hippen, R. Biassoni, A. Moretta, L. Moretta, J. C. Cambier, E. Vivier. 1996. Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J. Immunol. 156:4531.[Abstract]
  12. Vely, F., E. Vivier. 1997. Conservation of structural features reveals the existence of a large family of inhibitory cell surface receptors and noninhibitory/activatory counterparts. J. Immunol. 159:2075.[Abstract/Free Full Text]
  13. Burshtyn, D. N., E. O. Long. 1997. Regulation through inhibitory receptors: lessons from natural killer cells. Trends Cell Biol. 7:473.[Medline]
  14. Fry, A. M., L. L. Lanier, A. Weiss. 1996. Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C. J. Exp. Med. 184:295.[Abstract/Free Full Text]
  15. Rojo, S., D. N. Burshtyn, E. O. Long, N. Wagtmann. 1997. Type I transmembrane receptor with inhibitory function in mouse mast cells and NK cells. J. Immunol. 158:9.[Abstract]
  16. Bléry, M., H. Kubagawa, C. C. Chen, F. Vély, M. D. Cooper, E. Vivier. 1998. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. USA 95:2446.[Abstract/Free Full Text]
  17. Maeda, A., M. Kurosaki, M. Ono, T. Takai, T. Kurosaki. 1998. Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J. Exp. Med. 187:1355.[Abstract/Free Full Text]
  18. Vély, F., S. Olivero, L. Olcese, A. Moretta, J. E. Damen, L. Liu, G. Krystal, J. C. Cambier, M. Daëron, E. Vivier. 1997. Differential association of phosphatases with hematopoietic co-receptors bearing immunoreceptor tyrosine-based inhibition motifs. Eur. J. Immunol. 27:1994.[Medline]
  19. Shimizu, Y., R. DeMars. 1989. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J. Immunol. 142:3320.[Abstract]
  20. Litwin, V., J. Gumperz, P. Parham, J. H. Phillips, L. L. Lanier. 1993. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. J. Exp. Med. 178:1321.[Abstract/Free Full Text]
  21. Pear, W. S., G. P. Nolan, M. L. Scott, D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392.[Abstract/Free Full Text]
  22. Karlhofer, F. M., R. K. Ribaudo, W. M. Yokoyama. 1992. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66.[Medline]
  23. Ferrini, S., A. Cambiaggi, R. Meazza, S. Sforzini, S. Marciano, M. C. Mingari, L. Moretta. 1994. T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur. J. Immunol. 24:2294.[Medline]
  24. Long, E. O., S. Rosen-Bronson, D. R. Karp, M. Malnati, R. P. Sekaly, D. Jaraquemada. 1991. Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum. Immunol. 31:229.[Medline]
  25. Earl, P. L., B. Moss. 1988. Generation of recombinant vaccinia viruses. F. M. Ausubel, and R. Brent, and R. E. Kingston, and D. D. Moore, and J. G. Seidman, and J. A. Smith, and K. Struhl, eds. Current Protocols in Molecular Biology 16.17.1.. John Wiley & Sons, New York.
  26. Wagtmann, N., R. Biassoni, C. Cantoni, S. Verdiani, M. Malnati, M. Vitale, C. Bottino, L. Moretta, A. Moretta, E. O. Long. 1995. Molecular clones of the p58 natural killer cell receptor reveal Ig-related molecules with diversity in both the extra- and intracellular domains. Immunity 2:439.[Medline]
  27. Wange, R. L., R. Guitian, N. Isakov, J. D. Watts, R. Aebersold, L. E. Samelson. 1995. Activating and inhibitory mutations in adjacent tyrosines in the kinase domain of ZAP-70. J. Biol. Chem. 270:18730.[Abstract/Free Full Text]
  28. O’Shea, J. J., D. W. McVicar, T. L. Bailey, C. Burns, M. J. Smyth. 1992. Activation of human peripheral blood T lymphocytes by pharmacological induction protein-tyrosine phosphorylation. Proc. Natl. Acad. Sci. USA 89:10306.[Abstract/Free Full Text]
  29. Beauchemin, N., T. Kunath, J. Robitaille, B. Chow, C. Turbide, E. Daniels, A. Veillette. 1997. Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells. Oncogene 14:783.[Medline]
  30. Ono, M., S. Bolland, P. Tempst, J. V. Ravetch. 1996. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc{gamma}RIIB. Nature 383:263.[Medline]



This article has been cited by other articles:


Home page
J. Immunol.Home page
J. A. Hammond, L. A. Guethlein, L. Abi-Rached, A. K. Moesta, and P. Parham
Evolution and Survival of Marine Carnivores Did Not Require a Diversity of Killer Cell Ig-Like Receptors or Ly49 NK Cell Receptors
J. Immunol., March 15, 2009; 182(6): 3618 - 3627.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. H. Jia, J. Parodo, A. Kapus, O. D. Rotstein, and J. C. Marshall
Dynamic Regulation of Neutrophil Survival through Tyrosine Phosphorylation or Dephosphorylation of Caspase-8
J. Biol. Chem., February 29, 2008; 283(9): 5402 - 5413.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
P. Banerjee, G. Feuer, and E. Barker
Human T-Cell Leukemia Virus Type 1 (HTLV-1) p12I Down-Modulates ICAM-1 and -2 and Reduces Adherence of Natural Killer Cells, Thereby Protecting HTLV-1-Infected Primary CD4+ T Cells from Autologous Natural Killer Cell-Mediated Cytotoxicity despite the Reduction of Major Histocompatibility Complex Class I Molecules on Infected Cells
J. Virol., September 15, 2007; 81(18): 9707 - 9717.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Ward, M. Bonaparte, J. Sacks, J. Guterman, M. Fogli, D. Mavilio, and E. Barker
HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts
Blood, August 15, 2007; 110(4): 1207 - 1214.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
B. Treanor, P. M.P. Lanigan, S. Kumar, C. Dunsby, I. Munro, E. Auksorius, F. J. Culley, M. A. Purbhoo, D. Phillips, M. A.A. Neil, et al.
Microclusters of inhibitory killer immunoglobulin-like receptor signaling at natural killer cell immunological synapses
J. Cell Biol., July 3, 2006; 174(1): 153 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Chemnitz, A. R. Lanfranco, I. Braunstein, and J. L. Riley
B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs.
J. Immunol., June 1, 2006; 176(11): 6603 - 6614.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. E. Kirwan and D. N. Burshtyn
Killer Cell Ig-Like Receptor-Dependent Signaling by Ig-Like Transcript 2 (ILT2/CD85j/LILRB1/LIR-1)
J. Immunol., October 15, 2005; 175(8): 5006 - 5015.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
T. Yamaji, M. Mitsuki, T. Teranishi, and Y. Hashimoto
Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs
Glycobiology, July 1, 2005; 15(7): 667 - 676.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Isnardi, R. Lesourne, P. Bruhns, W. H. Fridman, J. C. Cambier, and M. Daeron
Two Distinct Tyrosine-based Motifs Enable the Inhibitory Receptor Fc{gamma}RIIB to Cooperatively Recruit the Inositol Phosphatases SHIP1/2 and the Adapters Grb2/Grap
J. Biol. Chem., December 10, 2004; 279(50): 51931 - 51938.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Avril, H. Floyd, F. Lopez, E. Vivier, and P. R. Crocker
The Membrane-Proximal Immunoreceptor Tyrosine-Based Inhibitory Motif Is Critical for the Inhibitory Signaling Mediated by Siglecs-7 and -9, CD33-Related Siglecs Expressed on Human Monocytes and NK Cells
J. Immunol., December 1, 2004; 173(11): 6841 - 6849.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. I. Bonaparte and E. Barker
Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules
Blood, October 1, 2004; 104(7): 2087 - 2094.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-i. Yusa, T. L. Catina, and K. S. Campbell
KIR2DL5 Can Inhibit Human NK Cell Activation Via Recruitment of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2)
J. Immunol., June 15, 2004; 172(12): 7385 - 7392.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. J. Lebbink, T. de Ruiter, A. Verbrugge, W. S. Bril, and L. Meyaard
The Mouse Homologue of the Leukocyte-Associated Ig-Like Receptor-1 Is an Inhibitory Receptor That Recruits Src Homology Region 2-Containing Protein Tyrosine Phosphatase (SHP)-2, but Not SHP-1
J. Immunol., May 1, 2004; 172(9): 5535 - 5543.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
A. Verbrugge, T. d. Ruiter, H. Clevers, and L. Meyaard
Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment
Int. Immunol., November 1, 2003; 15(11): 1349 - 1358.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Faure, D. F. Barber, S. M. Takahashi, T. Jin, and E. O. Long
Spontaneous Clustering and Tyrosine Phosphorylation of NK Cell Inhibitory Receptor Induced by Ligand Binding
J. Immunol., June 15, 2003; 170(12): 6107 - 6114.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-i. Yusa and K. S. Campbell
Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2) Can Play a Direct Role in the Inhibitory Function of Killer Cell Ig-Like Receptors in Human NK Cells
J. Immunol., May 1, 2003; 170(9): 4539 - 4547.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Kabat, F. Borrego, A. Brooks, and J. E. Coligan
Role That Each NKG2A Immunoreceptor Tyrosine-Based Inhibitory Motif Plays in Mediating the Human CD94/NKG2A Inhibitory Signal
J. Immunol., August 15, 2002; 169(4): 1948 - 1958.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Faure and E. O. Long
KIR2DL4 (CD158d), an NK Cell-Activating Receptor with Inhibitory Potential
J. Immunol., June 15, 2002; 168(12): 6208 - 6214.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. H. Lian, M. Maeda, S. Lohwasser, M. Delcommenne, T. Nakano, R. E. Vance, D. H. Raulet, and F. Takei
Orderly and Nonstochastic Acquisition of CD94/NKG2 Receptors by Developing NK Cells Derived from Embryonic Stem Cells In Vitro
J. Immunol., May 15, 2002; 168(10): 4980 - 4987.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-i. Yusa, T. L. Catina, and K. S. Campbell
SHP-1- and Phosphotyrosine-Independent Inhibitory Signaling by a Killer Cell Ig-Like Receptor Cytoplasmic Domain in Human NK Cells
J. Immunol., May 15, 2002; 168(10): 5047 - 5057.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Naper, S. Hayashi, G. Lovik, L. Kveberg, E. C. Niemi, B. Rolstad, E. Dissen, J. C. Ryan, and J. T. Vaage
Characterization of a Novel Killer Cell Lectin-Like Receptor (KLRH1) Expressed by Alloreactive Rat NK Cells
J. Immunol., May 15, 2002; 168(10): 5147 - 5154.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Bellon, F. Kitzig, J. Sayos, and M. Lopez-Botet
Mutational Analysis of Immunoreceptor Tyrosine-Based Inhibition Motifs of the Ig-Like Transcript 2 (CD85j) Leukocyte Receptor
J. Immunol., April 1, 2002; 168(7): 3351 - 3359.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Canavez, N. T. Young, L. A. Guethlein, R. Rajalingam, S. I. Khakoo, B. P. Shum, and P. Parham
Comparison of Chimpanzee and Human Leukocyte Ig-Like Receptor Genes Reveals Framework and Rapidly Evolving Genes
J. Immunol., November 15, 2001; 167(10): 5786 - 5794.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Dietrich, M. Cella, and M. Colonna
Ig-Like Transcript 2 (ILT2)/Leukocyte Ig-Like Receptor 1 (LIR1) Inhibits TCR Signaling and Actin Cytoskeleton Reorganization
J. Immunol., February 15, 2001; 166(4): 2514 - 2521.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. G. Sathish, K. G. Johnson, K. J. Fuller, F. G. LeRoy, L. Meyaard, M. J. Sims, and R. J. Matthews
Constitutive Association of SHP-1 with Leukocyte-Associated Ig-Like Receptor-1 in Human T Cells
J. Immunol., February 1, 2001; 166(3): 1763 - 1770.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Q. Zhang, P. N. Raghunath, E. Vonderheid, N. Odum, and M. A. Wasik
Lack of Phosphotyrosine Phosphatase SHP-1 Expression in Malignant T-Cell Lymphoma Cells Results from Methylation of the SHP-1 Promoter
Am. J. Pathol., October 1, 2000; 157(4): 1137 - 1146.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. P. Paul, L. S. Taylor, E. K. Stansbury, and D. W. McVicar
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2
Blood, July 15, 2000; 96(2): 483 - 490.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. D. Mousseau, D. Banville, D. L'Abbe, P. Bouchard, and S.-H. Shen
PILRalpha , a Novel Immunoreceptor Tyrosine-based Inhibitory Motif-bearing Protein, Recruits SHP-1 upon Tyrosine Phosphorylation and Is Paired with the Truncated Counterpart PILRbeta
J. Biol. Chem., February 11, 2000; 275(6): 4467 - 4474.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Pauza, K. M. Smith, H. Neal, C. Reilly, L. L. Lanier, and D. Lo
Transgenic Expression of Ly-49A in Thymocytes Alters Repertoire Selection
J. Immunol., January 15, 2000; 164(2): 884 - 892.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. H. Idris, H. R. C. Smith, L. H. Mason, J. R. Ortaldo, A. A. Scalzo, and W. M. Yokoyama
The natural killer gene complex genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing
PNAS, May 25, 1999; 96(11): 6330 - 6335.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burshtyn, D. N.
Right arrow Articles by Long, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burshtyn, D. N.
Right arrow Articles by Long, E. O.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS